Cleared Traditional

K802152 - PMT DEPTHALON DEPTH #2102

K802152 is the FDA 510(k) clearance for PMT DEPTHALON DEPTH #2102 by Progress Mankind Technology. It is a Class 2 Neurology device (product code GZL) cleared through the Traditional 510(k) pathway after a 72-day FDA review.

K802152 · Progress Mankind Technology · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1980
Decision
72d
Days
Class 2
Risk

K802152 is an FDA 510(k) clearance for the PMT DEPTHALON DEPTH #2102. Classified as Electrode, Depth (product code GZL), Class II - Special Controls.

Submitted by Progress Mankind Technology (Hopkins, US). The FDA issued a Cleared decision on November 19, 1980 after a review of 72 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1330 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Progress Mankind Technology devices

Submission Details

510(k) Number K802152 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 08, 1980
Decision Date November 19, 1980
Days to Decision 72 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
76d faster than avg
Panel avg: 148d · This submission: 72d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GZL Electrode, Depth
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1330
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.